Heart to heart – Faiez Zannad in his own words

A story from the Olink user community. Professor Faiez Zannad, one of the world’s foremost researchers in the area of heart failure, talks about his work, the importance of protein biomarkers in his field, and about his experiences of working with Olink over a number of years....

The COLLIBRI consortium

February 4, 2020 COLLIBRI is a consortium that looks to accelerate progress in the field of inflammatory bowel disease through the use of protein biomarkers, engaging academic and industrial partners to share both clinical samples and the data obtained from relevant studies. The aim...

Landmark publication on the human sectretome

In a landmark  study from Matthias Uhlén’s group at KTH in Stockholm, a novel map of all proteins secreted to human blood was described. This provides a first comprehensive listing of all proteins secreted by the human cells. This map provides a unique resource to study human biology and disea...

New upgrade of Olink’s NPX Manager software

In response to feedback from our customers, Olink has just released a signficantly upgraded version of our data import and processing software. Olink NPX Manager 2.0 features a range of improvements, including several that have been suggested by customers. Some of t...

Improvements to our Neuro Exploratory panel

In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a number of changes have been made to our Neuro Exploratory panel.  As data from this panel has accumulated, it became apparent that these two of the original assays would fit better in a pa...

Breakthrough publication on ovarian cancer

June 24, 2019. A breakthrough new publication from Enroth et al describes how broad screening of more than 590 proteins using Olink panels identified a high-accuracy 11-protein signature for ovarian cancer that could be verified in replication cohorts. These proteins were then devel...

Improvements to our Immuno-Oncology panel

In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a number of changes have been made to our Immuno-Oncology panel. Significant improvements in detectabilty have been made for two key existing assays, and four new assays that are highly rele...

A successful symposium in Utrecht

On Thursday May 2, 2019  UMC Utrecht and Olink held a symposium, “A proteomics perspective on Precision Medicine”. Around 60 scientists attended the event, which featured a series of outstanding presentations and an engaged and knowledgeable audience. The five customer tal...

Interview with Olink’s CEO in Business Trends

Business Trends magazine recently interviewed Olink Proteomics CEO, Jon Heimer and have published an article in which he outlines the company’s commitment to support the development of precision medicine by providing enabling solutions for protein biomarker discovery, development and implement...

Inflammation panel update

April 3, 2019. Olink® INFLAMMATION is the most widely used and most frequently cited Olink panel. After listening to feedback from our customers, we have made significant improvements to two key assays within this panel of 92 inflammation-related proteins. Our new assays for Tumor Necrosis Factor (T...